18α-glycyrrhetinic acid targets prostate cancer cells by down-regulating inflammation-related genes

International Journal of Oncology

Volumn 39, Issue 3, 2011, Pages 635-640

  Shetty, Aditya V ^a   Thirugnanam, Sivasakthivel ^a   Dakshinamoorthy, Gajalakshmi ^a   Samykutty, Abhilash ^a   Zheng, Guoxing ^a   Chen, Aoshuang ^a   Bosland, Maarten C ^b   Kajdacsy Balla, André ^b   Gnanasekar, Munirathinam ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

18 glycyrrhetinic acid; DU145; Inflammation; Invasion and prostate cancer

Indexed keywords

18ALPHA GLYCYRRHETINIC ACID; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; SYNAPTOTAGMIN I;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CHEMOPROPHYLAXIS; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CATTLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOWN-REGULATION; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCYRRHETINIC ACID; HUMANS; INFLAMMATION; MALE; MATRIX METALLOPROTEINASE 9; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; TRANSCRIPTION FACTOR RELA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79959927702     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1061     Document Type: Article

References (58)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Wang ZY and Nixon DW: Licorice and cancer. Nutr Cancer 39: 1-11, 2001. (Pubitemid 32880942)
3. Nomura T and Fukai T: Phenolic constituents of licorice (Glycyrrhiza species). Fortschr Chem Org Naturst 73: 1-158, 1998.
4. Mizutani K, Kuramoto T, Tamura Y, et al: Sweetness of glycyrrhetic acid 3-O-beta-D-monoglucuronide and the related glycosides. Biosci Biotechnol Biochem 58: 554-555, 1994.
5. Iida K, Uematsu Y, Suzuki K, Yasuno T, Hirata K and Ito K: [Properties of commercial licorice extracts used as a food additive]. Shokuhin Eiseigaku Zasshi 48: 112-117, 2007.
6. Carmines EL, Lemus R and Gaworski CL: Toxicologic evaluation of licorice extract as a cigarette ingredient. Food Chem Toxicol 43: 1303-1322, 2005. (Pubitemid 40884606)
7. Baltina LA: Chemical modification of glycyrrhizic acid as a route to new bioactive compounds for medicine. Curr Med Chem 10: 155-171, 2003.
8. Rackova L, Jancinova V, Petrikova M, et al: Mechanism of anti-inflammatory action of liquorice extract and glycyrrhizin. Nat Prod Res 21: 1234-1241, 2007. (Pubitemid 350302091)
9. Takahara T, Watanabe A and Shiraki K: Effects of glycyrrhizin on hepatitis B surface antigen: a biochemical and morphological study. J Hepatol 21: 601-609, 1994. (Pubitemid 24324037)
10. He JX, Akao T, Nishino T and Tani T The influence of commonly prescribed synthetic drugs for peptic ulcer on the pharmacokinetic fate of glycyrrhizin from Shaoyao-Gancao-tang. Biol Pharm Bull 24: 1395-1399, 2001. (Pubitemid 33133754)
11. Thirugnanam S, Xu L, Ramaswamy K and Gnanasekar M: Glycyrrhizin induces apoptosis in prostate cancer cell lines DU-145 and LNCaP. Oncol Rep 20: 1387-1392, 2008.
12. Niwa K, Lian Z, Onogi K, et al: Preventive effects of glycyrrhizin on estrogen-related endometrial carcinogenesis in mice. Oncol Rep 17: 617-622, 2007.
13. Harada S: The broad anti-viral agent glycyrrhizin directly modulates the fluidity of plasma membrane and HIV-1 envelope. Biochem J 392: 191-199, 2005.
14. Van Rossum TG, Vulto AG, De Man RA, Brouwer JT and Schalm SW: Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther 12: 199-205, 1998. (Pubitemid 28160013)
15. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H and Doerr HW: Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated Coronavirus. Lancet 361: 2045-2046, 2003. (Pubitemid 36695048)
16. Kim DH, Hong SW, Kim BT, Bae EA, Park HY and Han MJ: Biotransformation of glycyrrhizin by human intestinal bacteria and its relation to biological activities. Arch Pharm Res 23: 172-177, 2000.
17. Ikeda T, Yokomizo K, Okawa M, et al: Anti-herpes virus type 1 activity of oleanane-type triterpenoids. Biol Pharm Bull 28: 1779-1781, 2005. (Pubitemid 41324153)
18. Zeng CX, Yang Q and Hu Q: A comparison of the distribution of two glycyrrhizic acid epimers in rat tissues. Eur J Drug Metab Pharmacokinet 31: 253-258, 2006.
19. Ha YM, Cheung AP and Lim P: Chiral separation of glycyrrhetinic acid by high-performance liquid chromatography. J Pharm Biomed Anal 9: 805-809, 1991.
20. Chintharlapalli S, Papineni S, Jutooru I, McAlees A and Safe S: Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator-activated receptor {gamma} agonists in colon cancer cells. Mol Cancer Ther 6: 1588-1598, 2007. (Pubitemid 46954026)
21. Rossi T, Castelli M, Zandomeneghi G, et al: Selectivity of action of glycyrrhizin derivatives on the growth of MCF-7 and HEP-2 cells. Anticancer Res 23: 3813-3818, 2003. (Pubitemid 37474329)
22. Amagaya S, Sugishita E, Ogihara Y, Ogawa S, Okada K and Aizawa T: Comparative studies of the stereoisomers of glycyrrhetinic acid on anti-inflammatory activities. J Pharmacobiodyn 7: 923-928, 1984. (Pubitemid 15174849)
23. Sugishita E, Amagaya S and Ogihara Y Structure-activity studies of some oleanane triterpenoid glycosides and their related compounds from the leaves of Tetrapanax papyriferum on anti-inflammatory activities. J Pharmacobiodyn 5: 379-387, 1982. (Pubitemid 13231840)
24. Wang ZY, Agarwal R, Zhou ZC, Bickers DR and Mukhtar H: Inhibition of mutagenicity in Salmonella typhimurium and skin tumor initiating and tumor promoting activities in SENCAR mice by glycyrrhetinic acid: comparison of 18 alpha- and 18 beta-stereoisomers. Carcinogenesis 12: 187-192, 1991.
25. Darzynkiewicz Z, Sharpless T, Staiano-Coico L and Melamed MR: Subcompartments of the G1 phase of cell cycle detected by flow cytometry. Proc Natl Acad Sci USA 77: 6696-6699, 1980. (Pubitemid 11163467)
26. Newman SP, Foster PA, Stengel C, et al: STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells. Clin Cancer Res 14: 597-606, 2008. (Pubitemid 351226130)
27. Kureishi Y, Luo Z, Shiojima I, et al: The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6: 1004-1010, 2000.
28. Zhang H, Morisaki T, Matsunaga H, et al: Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-beta1 and MMPs. Clin Exp Metastasis 18: 343-352, 2000. (Pubitemid 32579404)
29. Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature 454: 436-444, 2008.
30. Hold GL and El-Omar EM: Genetic aspects of inflammation and cancer. Biochem J 410: 225-235, 2008.
31. Smith CW, Chen Z, Dong G, et al: The host environment promotes the development of primary and metastatic squamous cell carcinomas that constitutively express proinflammatory cytokines IL-1alpha, IL-6, GM-CSF, and KC. Clin Exp Metastasis 16: 655-664, 1998. (Pubitemid 29044588)
32. Ueda T, Shimada E and Urakawa T: Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol 29: 423-429, 1994. (Pubitemid 24262709)
33. Singh RK, Gutman M, Radinsky R, Bucana CD and Fidler IJ: Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 54: 3242-3247, 1994. (Pubitemid 24208936)
34. Ellerman JE, Brown CK, De Vera M, et al: Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 13: 2836-2848, 2007. (Pubitemid 46850704)
35. De Marzo AM, Platz EA, Sutcliffe S, et al: Inflammation in prostate carcinogenesis. Nat Rev Cancer 7: 256-269, 2007.
36. Nishino H, Kitagawa K and Iwashima A: Antitumor-promoting activity of glycyrrhetic acid in mouse skin tumor formation induced by 7,12-dimethylbenz[a] anthracene plus teleocidin. Carcinogenesis 5: 1529-1530, 1984. (Pubitemid 15218965)
37. Okamoto H, Yoshida D and Mizusaki S: Inhibition of 12-O-tetra- decanoylphorbol-13-acetate-induced induction in Epstein-Barr virus early antigen in Raji cells. Cancer Lett 19: 47-53, 1983. (Pubitemid 13100911)
38. Okamoto H, Yoshida D, Saito Y and Mizusaki S: Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase activity in mouse epidermis by sweetening agents and related compounds. Cancer Lett 21: 29-35, 1983. (Pubitemid 14203080)
39. Saito Y, Okamoto H, Mizusaki S and Yoshida D: Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced induction of Epstein-Barr virus early antigen in Raji cells by some inhibitors of tumor promotion. Cancer Lett 32: 137-144, 1986. (Pubitemid 16017123)
40. Abe H, Ohya N, Yamamoto KF, Shibuya T, Arichi S and Odashima S: Effects of glycyrrhizin and glycyrrhetinic acid on growth and melanogenesis in cultured B16 melanoma cells. Eur J Cancer Clin Oncol 23: 1549-1555, 1987.
41. Isaacs JT: Hormonally responsive versus unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and -G rat adenocarcinomas. Cancer Res 42: 5010-5014, 1982.
42. Hibasami H, Iwase H, Yoshioka K and Takahashi H: Glycyrrhetic acid (a metabolic substance and aglycon of glycyrrhizin) induces apoptosis in human hepatoma, promyelotic leukemia and stomach cancer cells. Int J Mol Med 17: 215-219, 2006.
43. Weidner N, Carroll PR, Flax J, Blumenfeld W and Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409, 1993. (Pubitemid 24058195)
44. Wakui S, Furusato M, Itoh T, et al: Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study. J Pathol 168: 257-262, 1992.
45. Lu H, Ouyang W and Huang C: Inflammation, a key event in cancer development. Mol Cancer Res 4: 221-233, 2006.
46. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002. (Pubitemid 36019639)
47. Veltri RW, Miller MC, Zhao G, et al: Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology 53: 139-147, 1999. (Pubitemid 29016629)
48. Pfitzenmaier J, Vessella R Higano CS, Noteboom JL, Wallace D Jr and Corey E Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 97: 1211-1216, 2003. (Pubitemid 36237306)
49. Uehara H, Troncoso P, Johnston D, et al: Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate 64: 40-49, 2005. (Pubitemid 40734737)
50. Kuniyasu H, Chihara Y, Kondo H, Ohmori H and Ukai R: Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep 10: 1863-1868, 2003.
51. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y and Uemura H: Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 64: 92-100, 2005. (Pubitemid 40734743)
52. Gnanasekar M, Thirugnanam S and Ramaswamy K: Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int J Oncol 34: 425-431, 2009.
53. Erlandsson Harris H and Andersson U: Mini-review: the nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol 34: 1503-1512, 2004.
54. Andersson U, Wang H, Palmblad K, et al: High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192: 565-570, 2000. (Pubitemid 30666257)
55. Schlueter C, Weber H, Meyer B, et al: Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol 166: 1259-1263, 2005. (Pubitemid 40524448)
56. Agresti A, Lupo R, Bianchi ME and Muller S: HMGB1 interacts differentially with members of the Rel family of transcription factors. Biochem Biophys Res Commun 302: 421-426, 2003. (Pubitemid 36397940)
57. Culig Z, Steiner H, Bartsch G and Hobisch A: Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 95: 497-505, 2005. (Pubitemid 41420180)
58. Araki S, Omori Y, Lyn D, et al: Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 67: 6854-6862, 2007. (Pubitemid 47105532)